EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension

Silvio Danese iD, Remo Panaccione iD, Maria T Abreu, David T Rubin iD, Subrata Ghosh iD, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire iD, Anjali Jain, Lorna Charles und 7 weitere

Journal of Crohn's and Colitis · 26.02.2024 · 18 (2) · 264-274

DOI: 10.1093/ecco-jcc/jjad146 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 31.08.2023. Verfasst von Silvio Danese und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Indans, Oxadiazoles. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Princeton, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds and Aims This interim analysis from the True North open-label extension [OLE] study examines efficacy and safety of approximately 3 years of continuous ozanimod treatment in patients with moderately to severely active ulcerative colitis.

Methods

Clinical responders after 52 weeks of ozanimod during the phase 3 True North study, who continued treatment in the OLE, were evaluated. Efficacy, including endoscopic and histological endpoints, was assessed during the OLE for approximately 2 additional years through OLE Week 94, using observed case [OC] and nonresponder imputation [NRI] analyses. Adverse events were monitored from True North baseline through OLE data cutoff and expressed as exposure-adjusted incidence rates.

Results

This analysis included 131 patients; 54% had achieved corticosteroid-free remission at True North Week 52. In OC analyses, clinical response, clinical remission, and corticosteroid-free remission were achieved by 91.4%, 69.1%, and 67.9% of patients, respectively, at OLE Week 94 [146 weeks of total treatment]. Similarly, endoscopic improvement, histological remission, and mucosal healing were achieved by 73.3%, 67.3%, and 56.3% of patients, respectively, at OLE Week 94. Efficacy rates were lower using NRI analyses, but maintenance of efficacy was demonstrated through OLE Week 94. No new safety signals emerged from this analysis. Serious infections, malignancy, cardiovascular events, and hepatic events occurred infrequently.

Conclusions

Among patients who achieved clinical response after 1 year of ozanimod treatment during True North, a high percentage sustained clinical and mucosal efficacy over 2 additional years in the OLE. No new safety signals were observed with long-term ozanimod use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeIndansOxadiazolesHumansAdrenal Cortex HormonesRemission InductionSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

S1P receptor modulatorUlcerative colitisozanimod

Substanzen

Adrenal Cortex HormonesIndansOxadiazolesozanimod

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Inflammatory Bowel Disease Unit, Gastrointestinal Research, Inflammatory Bowel Disease Clinic, Calgary, AB, Canada.
  • Crohn's & Colitis Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Inflammatory Bowel Disease Center, Chicago, IL, USA.
  • University College Cork, Cork, Ireland.
  • Department of Medicine, Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany.

ORCID-Profile: Silvio Danese, Remo Panaccione, David T Rubin, Subrata Ghosh, Severine Vermeire, Jean-Frederic Colombel, Miguel Regueiro

Förderung

  • Bristol Myers Squibb, Princeton, NJ, USA

Zitieren

APA

Danese, S., Panaccione, R., Abreu, M. T., Rubin, D. T., Ghosh, S., Dignass, A., Afzali, A., Wolf, D. C., Chiorean, M. V., Vermeire, S., Jain, A., Charles, L., Lawlor, G., Osterman, M. T., Wu, H., Canavan, J. B., Petersen, A., Colombel, J. F., & Regueiro, M. (2024). Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn's and Colitis, 18(2), 264-274. https://doi.org/10.1093/ecco-jcc/jjad146

Vancouver

Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, et al. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn's and Colitis. 2024;18(2):264-274. doi:10.1093/ecco-jcc/jjad146

BibTeX
@article{Danese2024,
  author = {Danese, Silvio and Panaccione, Remo and Abreu, Maria T and Rubin, David T and Ghosh, Subrata and Dignass, Axel and Afzali, Anita and Wolf, Douglas C and Chiorean, Michael V and Vermeire, Severine and Jain, Anjali and Charles, Lorna and Lawlor, Garrett and Osterman, Mark T and Wu, Hsiuanlin and Canavan, James B and Petersen, AnnKatrin and Colombel, Jean-Frederic and Regueiro, Miguel},
  title = {Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  volume = {18},
  number = {2},
  pages = {264--274},
  doi = {10.1093/ecco-jcc/jjad146}
}
Kostenlos starten →